Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Merck is definitely focused on buying up small innovative biotech companies in the immuno-oncology space. Keytruda is Merck's future, so anything positively paired with it in a combo therapy is fair game. Oncosec has fast-track designation and orphan drug designation for the PD-1 failure population. That means Oncosec has very deep value with their technology. Good interim Pisces results will bring a decent share price.
Merck is buying RIGONTEC for upfront cash and milestones totaling up to $450 million. I fOncosec were equally valued we would be a $5 or $6 dollar stock on our way to $15. I believe we will be moving over a buck today and higher. Start of Pisces trial will start shortly and we have events later this month and next but no pr yet. The ball should start rolling soon in anticipation. Good interim trial results and we fly high next year. People better get in now or be left behind.
Annalisa Jenkins looks like a good fit for Oncosec. Nice addition to the board. Background with Merck Serono and Bristol Myers, she has solid experience. She is the CEO of Dimension Therapeutics that is being bought out by Regenxbio for $85 milion. DMTX stock went from $1.20 to $3.80 in a matter of days. I like that she is now onboard with Oncosec
UPCOMING ONCOSEC EVENTS
Oncosec will be presenting at The Rodman and Renshaw Annual Global Investment Conference SEP. 10-12.
http://www.hcwainwright.com/assets/images/NYC_2017_General_v3.pdf
Dr. Sharron Gargosky for Oncosec Medical will be speaking at:
CELL AND GENE THERAPY EUROPE- SEP. 19-21
http://www.cgteurope.com/speakers/sharron-gargosky
Session:
Assessing the latest non-viral delivery technologies - can we define their real potential todeliver improvements on viral alternatives and/or to open up new indications and markets to gene therapy?
Dr. Gargosky has over 20 years of experience in clinical development and operations in the field of pharmaceutical and biologic development having managed global programs from early research phase through the U.S. Food & Drug Administration (FDA) approval process. She has been involved in FDA orphan drug approvals and is extensively published. Currently, Dr. Gargosky is the Chief Clinical and Regulatory Officer at OncoSec Medical Incorporated where she manages the immune-oncology program in metastatic melanoma and other pipeline programs, including the CMC, non clinical, clinical programs. Prior to that she was the Chief Technical and Operations Officer at Prima Biomed, Ltd., where she led the immuno-oncology program in ovarian and pancreatic cancer globally and throughout her career has served in positions of increasing clinical and scientific responsibility at biopharmaceutical companies including Pharmacia, Medicis, and Hyperion Therapeutics. Dr. Gargosky received her Ph.D. from the University of Adelaide, Australia and completed her postdoctoral fellowship at Stanford University.
Sharron Gargosky, Oncosec Medical will speak at:
Science 1st - Designing Nucleic Acid Medicines
JLABS San Diego
Wednesday, September 13, 2017 from 3:00 PM to 7:00 PM (PDT)
San Diego, CA
Johnson & Johnson Innovation, JLABS (JLABS) is bringing together leading San Diego scientific experts to share their data and insights advancing our understanding in this fascinating and complex space.
Most think that Merck would be the obvious suitor for Oncosec, but maybe J&J will have some interest too....since medical devices is their thing too. Would be nice to see a collaboration between J&J and Oncosec.
Oncosec will present at the 2017 Disruptive Growth Company Showcase NYC, SEP. 27:
http://disruptnyc.com/presenting-companies/
2nd Annual Biomarkers & Precision Medicine USA Congress
9-11 October 2017, San Diego, USA
Enrollment for Pisces trial should begin in September and they have a number of events scheduled for September that have not been announced yet. The $5 average price target on Oncosec will be a reality next year with decent data from the Pisces trial....absolutely.
Oncosec will present at the 2017 Disruptive Growth Company Showcase NYC, SEP. 27:
http://disruptnyc.com/presenting-companies/
Sharron Gargosky, Oncosec Medical will speak at:
Science 1st - Designing Nucleic Acid Medicines
JLABS San Diego
Wednesday, September 13, 2017 from 3:00 PM to 7:00 PM (PDT)
San Diego, CA
Johnson & Johnson Innovation, JLABS (JLABS) is bringing together leading San Diego scientific experts to share their data and insights advancing our understanding in this fascinating and complex space.
Most think that Merck would be the obvious suitor for Oncosec, but maybe J&J will have some interest too....since medical devices is their thing too. Would be nice to see a collaboration between J&J and Oncosec.
Dr. Sharron Gargosky for Oncosec Medical will be speaking at:
CELL AND GENE THERAPY EUROPE- SEP. 19-21
http://www.cgteurope.com/speakers/sharron-gargosky
Session:
Assessing the latest non-viral delivery technologies - can we define their real potential todeliver improvements on viral alternatives and/or to open up new indications and markets to gene therapy?
Dr. Gargosky has over 20 years of experience in clinical development and operations in the field of pharmaceutical and biologic development having managed global programs from early research phase through the U.S. Food & Drug Administration (FDA) approval process. She has been involved in FDA orphan drug approvals and is extensively published. Currently, Dr. Gargosky is the Chief Clinical and Regulatory Officer at OncoSec Medical Incorporated where she manages the immune-oncology program in metastatic melanoma and other pipeline programs, including the CMC, non clinical, clinical programs. Prior to that she was the Chief Technical and Operations Officer at Prima Biomed, Ltd., where she led the immuno-oncology program in ovarian and pancreatic cancer globally and throughout her career has served in positions of increasing clinical and scientific responsibility at biopharmaceutical companies including Pharmacia, Medicis, and Hyperion Therapeutics. Dr. Gargosky received her Ph.D. from the University of Adelaide, Australia and completed her postdoctoral fellowship at Stanford University.
Noble Capital Marlets has a Buy rating and $5 price target on Oncosec as of 8/26/17
http://www.noblelinx.com/x/research/coverage_lists/noble_financial_coverage_universe.pdf
Oncosec will be presenting at The Rodman and Renshaw Annual Global Investment Conference SEP. 10-12.
http://www.hcwainwright.com/assets/images/NYC_2017_General_v3.pdf
I agree. Oncosec has more going for them than the market is willing to give credit. They are quietly getting patents in order. Oncosec shelled out millions of dollars in research to advance the electroporation technology they have now. I think it will pay off in the future. I believe we will eventually get a real explosive move when the market has reason to wake up to this. When we get FDA approval will be the start of that move. Their is so much potential with this company it would be a real shame if it doesn't happen. I still believe it will happen.
Sabby still holding most of their shares, only reduced by around 7,000 shares. Vanguard still holding over 400,000 shares. Millennium added 219,000 shares. So not everybody has bailed this past quarter which is nice to know.
Oncosec is in the Shithouse at the moment because of the Pisces trial delay. We are seeing some institutional selling too because of this. Vanguard has reduced by 20% and some others have sold out. I don't see any change in Sabby holdings yet but I wouldn't be surprised if they reduced some. Hopefully the clinical sites will be running soon and we get full enrollment by year end. Next year will be the year of data release and do or die time. If we get positive results it will not matter that we had this delay. We will have a much higher market cap, and maybe some day 20 Billion dollar market cap may be a possibility if Oncosec technology proves to be ground-breaking, you never know. I am still positive about their future.
IR response to question regarding PISCES trial delay:
"we will address your question along with many others in our upcoming Quarterly Newsletter on our website"
The last newsletter was in January, so the next one better come soon with some positive information.
An ATM offering is probably the best we could have hoped for right now. That should cover them for 2 quarters. As soon as they announce the start of the registration trial I would think they will take advantage of a share spike and do some selling. I think we may see less dilution than people think right here. Any positive developments such as more prestigious conferences or new TAP collaborations etc. will be a chance for Oncosec to sell on SP spikes. If we get good interim results after 6 months data then we will be set up to test much higher levels. It will all rest on the data at this point. I am still a believer. If this is indeed an inflection year and I believe it really is then we are truly at the bottom regarding share price. I also like that for once there are no warrants attached to this offering.
Titan, I am keeping an eye out for that other milestone you mentioned which could be a partnership with ROCHE in TNBC combo study with TECENTRIQ. I think this will happen. Expect the unexpected here.
Oncosec now has the PISCES trial listed on their Current Clinical Trials link on their website:
Multicenter Phase II , Open-Label Trial of Intratumoral pIL-12 Plus Electroporation in Combination With Intravenous Pembrolizumab in Patients With Stage III/IV Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment (PISCES)
Any day now we should get the PR about the trial opening for enrollment.
Patience folks, we will have our day in the sun eventually.
Dawson James Securities initiated coverage on Oncosec today at $5 price target. They are pretty active as placement agents so I would expect things to go down like this soon...just my own speculations here.
a- Oncosec announces start of registration trial in July.
b- share price pops briefly, only sustainable if they announce additional licensing deals of substance.
c- Oncosec announces capital raise of between 6 to 10 million dollars. $1.10- $1.20 range. Dawson James will be the placement agent.
d- Oncosec releases interim results at 6 months.
e- we all sit with our fingers crossed and poop our pants waiting for good or bad results.
I just want them to get the capital raise over with and hopefully announce some decent partnerships soon. We are due for some good news, been way too quiet these days. The big news for July will be start of registration trial because they have not announced any events for July. I think all energy is being spent getting the trial started and that is a good thing.
Go Oncosec! Good luck to ALL here!
(I love seeing that ask price at 17.8 after hours. One day hopefully that will be a reality with a takeover bid or we get the FDA seal of approval with positive trial results)
100 share sell blocks intentionally keeping this down. Don't be fooled people, we are headed upwards.
I think Heat Biologics may wind up being another TAP deal in the future. This data from Heat/Oncosec collaboration was announced a few months ago and yielded positive results; Heat's Vaccines delivered directly into the tumor using Oncosec's Immunopulse platform.....just a reminder
http://www.bizjournals.com/triangle/news/2017/04/06/oncosec-collaboration-data-promising-for-embattled.html
Every additional positive data readout/result from other companies using Oncosec's Immunopulse will only increase Oncosec's value in the future. Over time this will build like a snowball.
That is possible we are getting some interest because of HTBX news.
Fear of dilution has kept ONCS share price down. HTBX grant money news today has them up 20%, If Oncosec can secure funds without dilution as they have said they are trying to do maybe we get a surprise like HTBX today.
A lot of buying above $1.30. We are definitely on the move today.
I think we are spring-loaded here on the verge of news.
Damn, Bust a Move baby!
yup, not open for enrollment yet, any day now this should change.
I am confident we are headed in the right direction, we just need a decent announcement to break us through to a new level higher....we deserve it.
nope...we were due for a ride back up and we are obviously in a new uptrend if you look at the recent upward swing from the bottom.
Short term traders are probably starting to sell and this will end up higher at the end of the day after profit taking subsides.
Also possibly a news leak of some sort and maybe we get some sort of pr after market close. Somebody always knows something before the little guys do.
Start of registration trial any time now will put us on a definitive track timeless, 6 to 9 months to data release, sink or swim time is getting started and I think people are going to continue to buy in at this basement price. Keep an eye on SEC filings next quarter and see who has picked up shares at the bottom. High risk here but if we get good results from the registration trial were are solid gold and the sky is the limit.
Buy Volume today looking strong too.
We are headed for a decent breakout from here I think. Would love to see a nice chunk of grant money hit us like HTBX, something out of the blue to supercharge Oncosec stock price.
Volume updates must be slow today. I think we will see stronger volume in the next few days. Anticipation is building here. Oncosec has been very quiet lately. We should be getting event news for July soon and hopefully the start of open enrollment for the registration trial.
Buy Volume getting stronger now.
Stock price really bouncing around today, maybe in anticipation of the registration trial enrollment starting any time now, just waiting for an announcement. Wound up like a rubber band here.
Buy Volume much higher than Sell Volume today....looking good here.
I believe that Oncosec will be allowed to share interim data for the registration trial because it is an Open Label trial....correct me if I am misinformed about this.
So at a lower price you would buy this POS. I'm sure if you are selling many will be buying your shares. I am sure Vanguard is currently adding to their position right now. Deep value here.
the study is: A Multicenter Phase 2, Open-Label Trial of Intratumoral pIL-12 Plus Electroporation in Combination With Intravenous Pembrolizumab in Patients With Stage III/IV Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment.
Oncosec can release data as it comes in so we may see data by year end.